Effect of entecavir or lamivudine treatment on hepatocellular carcinoma incidence in patients with chronic hepatitis B:a meta-analysis
ZHOU Hui-rong
RONG Xiao-xiang
JIA Li-ting
YANG Ke-ke
QIN Yu-juan
ZHU Hua
Abstract：Objective To systematically evaluate the effect of entecavir ( ETV) or lamivudine ( LAM) on the hepato-cellular carcinoma ( HCC) incidence of patients with chronic hepatitis B ( CHB) .Methods Using key words of entecavir and lamivudine, we systematically searched in PubMed from January 1st, 2000 to May 30th, 2015 with species limited in human.The included articles must satisfied the following criterions:①definite diagnosed adult patients (age≥16 years),②treatment protocols:take ETV or LAM orally ,③experimental design: retrospective or prospective case-control study ,④ clearly diagnostic criteria and relative dates must be provided in HCC patients during follow -up.HCC incidence after be-ing treated with ETV or LAM was compared .Results A total of 751 English literatures conformed to the search condition , and 3 studies including 5 014 patients were selected in this analysis , and 2327 cases of them treated with ETV ( ETV group) , 2687 cases with LAM ( LAM group) .No significant publication bias was found both in Begg test and funnel plot (P=0.602).Compared with the LAM group, both fixed effect model and random effect model showed the incidence of HCC in ETV group was lower (fixed effect model:RR=0.547, 95%CI:0.450-0.666, P=0.000;random effect model:RR=0.444, 95%CI:0.210-0.937, P=0.033).Conclusion Both ETV and LAM treatment can reduce the risk of HCC in CHB patients , but the effect of ETV is better .
Keywords：chronic hepatitis Bhepatocellular carcinomaentecavirlamivudinemeta analysis
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 30-32 )